VBI Vaccines, Inc. - Ordinary Shares (VBIV): Price and Financial Metrics


VBI Vaccines, Inc. - Ordinary Shares (VBIV): $3.96

0.04 (+1.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VBIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 486

in industry

VBIV POWR Grades


  • Momentum is the dimension where VBIV ranks best; there it ranks ahead of 34.68% of US stocks.
  • VBIV's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
  • VBIV's current lowest rank is in the Quality metric (where it is better than 1.34% of US stocks).

VBIV Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VBIV is 0.01 -- better than just 8.08% of US stocks.
  • VBIV's price/sales ratio is 1,052.21; that's higher than the P/S ratio of 99.05% of US stocks.
  • As for revenue growth, note that VBIV's revenue has grown -58.39% over the past 12 months; that beats the revenue growth of just 5.35% of US companies in our set.
  • Stocks that are quantitatively similar to VBIV, based on their financial statements, market capitalization, and price volatility, are GEVO, OTIC, FENC, CAPR, and SVRA.
  • VBIV's SEC filings can be seen here. And to visit VBI Vaccines Inc's official web site, go to www.vbivaccines.com.

VBIV Stock Price Chart Interactive Chart >

Price chart for VBIV

VBIV Price/Volume Stats

Current price $3.96 52-week high $6.93
Prev. close $3.92 52-week low $2.07
Day low $3.93 Volume 672,950
Day high $4.02 Avg. volume 5,358,132
50-day MA $3.14 Dividend yield N/A
200-day MA $3.14 Market Cap 1.01B

VBI Vaccines, Inc. - Ordinary Shares (VBIV) Company Bio


VBI Vaccines Inc. develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.


VBIV Latest News Stream


Event/Time News Detail
Loading, please wait...

VBIV Latest Social Stream


Loading social stream, please wait...

View Full VBIV Social Stream

Latest VBIV News From Around the Web

Below are the latest news stories about VBI Vaccines Inc that investors may wish to consider to help them evaluate VBIV as an investment opportunity.

10 Best Biotech Penny Stocks to Buy Now

In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […]

Yahoo | June 14, 2021

VBI Vaccines (VBIV) is in Overbought Territory: What's Next?

VBI Vaccines (VBIV) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Yahoo | June 11, 2021

VBI Vaccines Announces Results of Annual General Meeting

VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 9, 2021 (the "Meeting").

Yahoo | June 9, 2021

VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status

VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

Yahoo | June 9, 2021

VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that two abstracts featuring data from the Company’s prophylactic and therapeutic hepatitis B (HBV) candidates have been accepted for presentation at The Digital International Liver Congress™ 2021 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 23-26, 2021.

Yahoo | June 9, 2021

Read More 'VBIV' Stories Here

VBIV Price Returns

1-mo 31.13%
3-mo 14.45%
6-mo 22.41%
1-year 51.15%
3-year 12.50%
5-year -6.16%
YTD 44.00%
2020 99.28%
2019 -13.75%
2018 -62.53%
2017 37.74%
2016 27.05%

Continue Researching VBIV

Here are a few links from around the web to help you further your research on VBI Vaccines Inc's stock as an investment opportunity:

VBI Vaccines Inc (VBIV) Stock Price | Nasdaq
VBI Vaccines Inc (VBIV) Stock Quote, History and News - Yahoo Finance
VBI Vaccines Inc (VBIV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8571 seconds.